CNTA250117P5000
- 0.00
- 0.000.00%
Centessa Pharmaceuticals Newsroom
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Centessa Pharmaceuticals (CNTA)
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Centessa Pharmaceuticals Initiated at Buy by TD Cowen
TD Cowen Initiates Centessa Pharmaceuticals(CNTA.US) With Buy Rating
B.Riley Financial Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $33
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $24
Centessa Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $28
Morgan Stanley Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating
B.Riley Financial Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $33
Centessa Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Oppenheimer Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $24
Morgan Stanley Upgrades Centessa Pharmaceuticals(CNTA.US) to Buy Rating, Raises Target Price to $26
B.Riley Financial Initiates Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $33
Buy Rating for Centessa Pharmaceuticals on Promising ORX750 Drug Advancements and Market Expansion Potential
Centessa Pharmaceuticals Is Maintained at Outperform by BMO Capital